Rare Disease Day 2026: From Awareness to Access in a Volatile Year for Patients and Specialized Therapies

Rare Disease Day began in 2008, launched in Europe by EURORDIS to shine a light on millions living with conditions that were often misunderstood, misdiagnosed or ignored. Nearly two decades later, the rare disease community is at a critical juncture. Science has advanced and awareness has grown, with global observance spanning over 100 countries. At the same time, 2026 is proving to be a volatile year in healthcare: access to specialized therapies is even more complex as regulators, payers and employers grapple with the implications of breakthrough treatments against the backdrop of changing regulations and commercial models. 

This year more than ever, Rare Disease Day — observed February 28 — is not just about awareness but is also a call to action for patients, families, employers, payers and policymakers to modernize the systems that shape access to care. It must focus on connecting innovation with the infrastructure that governs approval, coverage and affordability.

A volatile environment for 2026

Rare disease stakeholders are under heightened pressure this year, with regulators signaling increased scrutiny of new approvals. Several orphan drug and gene therapies were hit with FDA review challenges at the end of 2025, for example, highlighting the tension between rapid innovation and regulatory scrutiny. 

Even with approval, cost remains a major challenge. Specialty drugs tied to rare conditions are expected to constitute up to 40% of the total health cost trend in 2026. As payers  manage a growing pipeline of high-cost specialty launches, with self-insured employers absorbing a disproportionate share of rare disease spend, they are left looking for new models and approaches to support members in need of new treatments. 

Patients cannot afford delay and plan sponsors cannot ignore financial sustainability. Rare Disease Day 2026 arrives at this inflection point, urging stakeholders to move beyond visibility toward operational alignment.

Powered by something personal 

Like many families affected by rare disease, my experience didn’t come from pamphlets or textbooks. It came from years of watching loved ones endure misdiagnosis and loss. Growing up, we lost multiple relatives to a disease we didn’t yet understand. Only after my uncle’s diagnosis was finally corrected did we learn we were facing Alpha-1 Antitrypsin Deficiency (Alpha-1), a rare genetic disorder caused by a misfolded protein that affects the lungs and liver.

Years of misdiagnosis reshaped our lives. We became caregivers, researchers and advocates by necessity. I watched my father battle the disease and undergo a double lung transplant. That experience transformed my perspective, from managing rare disease within my own family to working to improve the systems that determine who gets diagnosed, treated or is left waiting. Engaging with the patient community revealed a powerful truth: our story was not unique, and patterns of delayed diagnosis, fragmented care and access barriers reflected broader systemic gaps. 

With today’s technology and access, rare disease communities have more tools than ever to connect, mobilize and partner with scientists and physicians to change the trajectory of living with their respective disease. Patient communities no longer need to wait passively; they can drive progress. 

Innovation is accelerating — but access is strained

The pace of rare disease innovation is unprecedented. Dozens of cell and gene therapies are expected to reach the market by 2030. Even with improvements in regulatory pathways, approval does not guarantee access. 

Current reimbursement systems and benefit structures were not designed for one-time gene therapies, high-cost biologics or ultra-specialized treatments. As innovation accelerates, coverage frameworks struggle to adapt. The result is a widening gap between scientific capability and real-world availability. Patients experience delays from prior authorization, inconsistent coverage, shifting formularies and high out-of-pocket costs. 

Biopharma innovators cannot blindly follow the old commercialization playbook. They need to educate providers and payers much earlier in the process.  Innovation has scaled; access infrastructure has not.

Coverage does not equal care

For rare disease patients, FDA approval is only the start. Administrative barriers, utilization management protocols and tiered cost-sharing structures can delay or restrict therapy.

For common conditions, delays may be inconvenient. For rare diseases, delays can mean irreversible progression. Many patients have no alternative option, and some have waited decades for a viable treatment. Access must be intentional – designed with the same urgency as innovation.

Self-insured employers now play a central role in determining whether specialized therapies reach patients. They sit at the intersection of workforce health, benefit design and financial stewardship.

Rare disease strategy must be proactive rather than reactive. That means investing in high-touch specialty pharmacy management to support adherence, streamlining prior authorization for clearly defined conditions and evaluating cost-sharing tiers that may create financial toxicity.

Forward-thinking employers are exploring direct relationships with centers of excellence, leveraging data to understand workforce impact and collaborating with advocacy organizations to better align benefits with patient realities.

These are structural decisions, not symbolic ones, that determine whether specialized therapies translate into meaningful outcomes.

From fragmentation to alignment

Rare disease exposes structural fractures: siloed stakeholders, inconsistent data sharing, opaque pricing, and misaligned incentives.

Addressing these gaps requires coordination. Provider education can shorten diagnostic journeys. Responsible data exchange helps payers understand disease burden and justify coverage decisions. Transparent, predictable policies reduce administrative friction and accelerate therapy.

Collaboration – not confrontation – is essential in a volatile year.

Lived experience as a catalyst for change

My family’s experience with Alpha-1 taught me that lived experience carries policy relevance. It reveals system failures, underscores the urgency behind benefit design and reminds stakeholders that behind every review is a person waiting for care.

Rare Disease Day began as a movement to make rare visible. In 2026, visibility is no longer enough. The question is whether our access models will evolve as quickly as our science.

This year will test the resilience of patients, the flexibility of payers and the foresight of employers. If innovation continues to accelerate, coverage frameworks must modernize alongside it.

Awareness opened the door nearly two decades ago. Rare Disease Day 2026 challenges us to walk through it and build an access model capable of supporting the specialized therapies patients have waited far too long to receive.

Photo: erhui1979, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.